Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) has a beta value of -0.55 and has seen 1.22 million shares traded in the last trading session. The company, currently valued at $295.63M, closed the last trade at $3.45 per share which meant it lost -$0.04 on the day or -1.15% during that session. The AMLX stock price is -478.26% off its 52-week high price of $19.95 and 54.2% above the 52-week low of $1.58. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.2 million shares traded. The 3-month trading volume is 1.09 million shares.
The consensus among analysts is that Amylyx Pharmaceuticals Inc (AMLX) is Buy stock at the moment, with a recommendation rating of 2.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.59.
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) trade information
Over the past 30 days, the shares of Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) have changed -13.75%. Short interest in the company has seen 2.48 million shares shorted with days to cover at 3.19.
Wall Street analysts have a consensus price target for the stock at $9, which means that the shares’ value could jump 61.67% from current levels. The projected low price target is $4.0 while the price target rests at a high of $11.0. In that case, then, we find that the current price level is -218.84% off the targeted high while a plunge would see the stock gain -15.94% from current levels.
Amylyx Pharmaceuticals Inc (AMLX) estimates and forecasts
Figures show that Amylyx Pharmaceuticals Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 75.13% over the past 6 months, with this year growth rate of -712.86%, compared to 17.30% for the industry. Revenue growth from the last financial year stood is estimated to be -76.88%.
Year-ago sales stood 108.45M and 88.64M respectively for this quarter and the next, and analysts expect sales will shrink by -100.00% for the current quarter and -76.88% for the next.
AMLX Dividends
Amylyx Pharmaceuticals Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX)’s Major holders
Insiders own 11.44% of the company shares, while shares held by institutions stand at 65.47% with a share float percentage of 73.92%. Investors are also buoyed by the number of investors in a company, with Amylyx Pharmaceuticals Inc having a total of 153.0 institutions that hold shares in the company. The top two institutional holders are VANGUARD GROUP INC with over 4.22 million shares worth more than $8.03 million. As of 2024-06-30, VANGUARD GROUP INC held 6.2251% of shares outstanding.
The other major institutional holder is AQR CAPITAL MANAGEMENT LLC, with the holding of over 3.34 million shares as of 2024-06-30. The firm’s total holdings are worth over $6.35 million and represent 4.9237% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and abrdn Healthcare Investors . As of Sep 30, 2024 , the former fund manager holds about 2.64% shares in the company for having 1.81 shares of worth $6.25 million while later fund manager owns 1.37 shares of worth $4.72 million as of Sep 30, 2024 , which makes it owner of about 2.00% of company’s outstanding stock.
